# Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

> **NCT02940301** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02940301
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-12-20
- **Primary completion:** 2026-08-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02940301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02940301, "Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02940301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*